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Use of CD25 as an immunohistochemical marker
for acquired ocular  toxoplasmosis
Uso do CD25 como um marcador imuno-histoquímico de toxoplasmose ocular adquirida
CRISTINA MIYAMOTO1,2, RUBENS BELFORT MATTOS NETO2, SEBASTIAN DI CESARE1, RUBENS BELFORT JUNIOR2, MIGUEL N. BURNIER JR.1,2
INTRODUCTION
T oxoplasmosis is caused by the intracellular protozoan To-xoplasma gondii (1), that infects up to a third of the world’spopulation(2). Infections may be acquired congenitally or
through the ingestion or handling of undercooked or raw infec-
ted meat, contaminated vegetables or water(1-3). The disease is
asymptomatic in many immunocompetent hosts, however
ocular lesions may be present in up to 20% of infected indivi-
duals(1). In immunocompromised patients, the disease often
manifests as encephalitis and also ophthalmic lesions(4-6).
Ocular involvement occurs in either congenital or acqui-
red infection. In the United States, infection occurs in 2/1000
pregnancies, with a transplacental infection rate ≤ 50%(6-7). In
France, the estimated yearly incidence of contamination in
women during pregnancy is 6-7/1000 and of congenital toxo-
plasmosis is approximately 0.1% of births(8). Seventy percent of
infants with congenital infection show chorioretinal scars(7).
Although most of the cases in adults were thought to be a
consequence of the reactivation of congenital lesions(9), several
studies indicate that ocular disease may be caused by T. gondii
infection after birth(1,6,10-12). In fact, most cases in Brazil are a conse-
quence of post-natal infection(6).
Ocular toxoplasmosis is characterized by a necrotizing
retinitis with oval or circular lesions(4). It is often impossible to
determine the congenital or acquired nature of this particular
uveitic process(1-2,13-15). Late onset acquired ocular toxoplasmosis
may manifest itself up until at least thirteen years after primary
infection(16 -17).
Interleukin-2 (IL-2) plays an important role in the prolife-
ration and survival of recently activated effector T cells(18). IL-2
in peripheral blood has been described as a possible marker for
acquired toxoplasmosis(7). Yamamoto et al. evaluating blood
samples from 136 subjects with positive and negative titers of
antibody (IgM and IgG) to T. gondii, found that production of
IL-2 and interferon-g by peripheral blood mononuclear cells
ABSTRACT
Purpose: Toxoplasmosis is the most common cause of posterior infectious
uveitis worldwide. It is often impossible to determine its congenital or acquired
nature. Interleukin-2 (IL-2) in peripheral blood has been described as a possible
marker for acquired toxoplasmosis. The purpose of this study is to evaluate the
histopathological characteristics of ocular toxoplasmosis cases using CD25 as
a marker for the expression of interleukin-2.
Methods: Ten formalin-fixed, paraffin-embedded enucleated globes from ten
immunocompetent patients with clinical diagnosis of toxoplasmosis were
evaluated. Four patients had the acquired form of ocular toxoplasmosis (posi-
tive IgM) while six were IgM negative and IgG positive for toxoplasmosis. Histo-
pathological slides were reviewed for the extension of the retinal necrosis,
number of toxo cysts, the granulomatous inflammatory reaction, the presence
of T and B cells within the choroid and the IL-2 expression. Immunohistochemistry
using monoclonal antibodies was performed to observe the expression of
CD4, CD8, CD20, CD25, and CD68.
Results: The histopathological evaluation disclosed no differences between
acquired and the other ocular toxoplasmosis cases regarding the characteristics
studied. However, CD25 showed a higher expression of IL-2 on the 4 acquired
cases of ocular toxoplasmosis compared to the remainders.
Conclusions: To the best of our knowledge, this is the first report showing that
the use of CD25 as a marker for interleukin-2 could differentiate acquired ocular
toxoplasmosis.
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RESUMO
Objetivo: Toxoplasmose é a causa mais comum de uveíte posterior no mundo.
Em grande parte dos casos, não é possível determinar se a doença ocular é
devida a um quadro congênito ou adquirido. Interleucina-2 (IL-2) no sangue
periférico foi descrita como um possível marcador de toxoplasmose adquirida.
O objetivo deste estudo foi avaliar as características de casos de toxoplasmose
usando CD25 como um marcador da expressão de interleucina-2.
Métodos: Dez olhos enucleados fixados com formalina e embebidos em para-
fina de dez pacientes imunocompetentes com diagnóstico clínico de toxo-
plasmose ocular foram examinados. Quatro pacientes tinham a forma adqui-
rida (IgM positivo) enquanto 6 eram IgM negativo e IgG positivo para to-
xoplasmose. Cortes histopatológicos foram avaliados quanto a extensão de
necrose retiniana, número de cistos de T. gondii, reação granulomatosa e
presença de células B e T na coróide, bem como a expressão de interleucina-
2. Estudo imuno-histoquímico utilizando anticorpos monoclonais foi realizado
para determinar a expressão de CD4, CD8, CD20, CD25 e CD68. 
Resultados: A avaliação histopatológica não mostrou diferenças entre os
casos de toxoplasmose ocular com relação às características avaliadas mencio-
nadas anteriormente. Entretanto, CD25 revelou maior expressão de interleu-
cina-2 nos 4 casos adquiridos comparado com os demais.
Conclusões: Expressão elevada de CD25 foi encontrada em todos os casos de
toxoplasmose ocular adquirida. Assim, o uso de CD25 como marcador da
interleucina-2 pode ser uma ferramenta útil para diferenciar toxoplasmose
ocular congênita de adquirida.
Descritores: Toxoplasmose ocular/imunologia; Imuno-histoquímica; Toxoplas-
mose ocular/congênito; Toxoplasmose ocular/diagnóstico; Interleucina-2/uso
diagnóstico; Antígenos CD5; Diagnóstico diferencial; Antígenos de diferenciação
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from patients with probable congenital toxoplasmosis was de-
creased, compared to patients with presumed acquired infec-
tion(7).
CD25 is a transmembrane protein which forms the alpha
chain of the IL-2 receptor(19-20). It plays a crucial role in IL-2 homeo-
stasis(20). The goal of this study was to examine the immunohis-
tochemistry expression of CD25 in enucleated eyes of patients
with toxoplasmosis, considering the possibility of evaluating
histopathologic specimens (Yamamoto et al. studied blood sam-
ples by ELISA(7). In addition we aimed to determine whether
CD25, as a marker for the expression of IL-2, could differen-
tiate acquired from congenital ocular toxoplasmosis.
METHODS
Ten formalin-fixed paraffin-embedded enucleated globes
from ten immunocompetent patients with clinical diagnosis
of toxoplasmosis were evaluated. The globes were obtained
from the Henry C. Witelson Ocular Pathology Laboratory. All
the subjects had the titers of antibody (IgM or IgG) to T. gondii
determined. Age, gender and number of recurrences was also
retrieved.
Histopathological slides were reviewed by one experien-
ced ocular pathologist (MNB) for the extension of the retinal
necrosis, number of toxo cysts, the granulomatous inflammato-
ry reaction and the presence of T and B cells within the choroid,
as well as the IL-2 expression.
Expression of CD4, CD8, CD20, CD25 and CD68 was also
evaluated by the avidin-biotin complex (ABC) immunohisto-
chemistry method, using monoclonal antibodies (CD4, CD8,
CD 20, CD 25 and CD68) from Dako Laboratory (SPA-830; Stressgen,
Victoria, BC, Canada).
The study protocol followed the precepts of the Declara-
tion of Helsinki and was approved by the Research Institute of
the McGill University Hospital Centre.
RESULTS
Clinical information for all ten patients included in the
study is summarized in table 1. Histopathological examination
of the enucleated eyes revealed extensive areas of retinal
necrosis with accompanying choroidal inflammation (Figure 1).
Toxo cysts could be identified within the necrotic retina.
Eosinophilic deposits between the retinal pigmented epithe-
lium and the Bruch’s membrane could be seen, representing
areas of necrosis. However, there were no differences between
acquired and IgM negative ocular toxoplasmosis regarding
the extension of retinal necrosis and the number of toxo cysts.
The granulomatous choroiditis and the presence of T and B
lymphocytes were also similar in all cases.
Regarding immunohistochemical profiling (Graph 1), CD25
was positive (Figure 2) in all (4) IgM positive cases, but only in
two out of the six IgM negative patients. No differential expres-
sion was seen for CD4 (Figure 3) and CD68.
DISCUSSION
Infection by T. gondii can be diagnosed indirectly with
serological methods or directly by histology, isolation of the
parasite or its material (polymerase chain reaction (PCR), hy-
bridization)(2,6,21).
The diagnosis of ocular toxoplasmosis is mainly clinical(3,22).
The presence of anti T. gondii IgG antibodies does not confirm
the toxoplasmic etiology, but a negative IgG generally dis-
cards the possibility(3). IgG antibodies are detectable for the
life of the individual and there is a high prevalence of such
antibodies in the general population. On the other hand, IgM
antibodies may be detectable for many years in certain pa-
tients(22-25).
Pathological diagnosis of ocular toxoplasmosis can be esta-
blished by chorioretinal biopsies or diagnostic enuclea-
tion(3,26). The toxoplasma cysts are identified with haematoxylin
and eosin, immunohistochemistry using polyclonal or mono-
clonal antibodies(3,27), or by PCR(17). Histologically, ocular toxo-
plasmosis often presents extensive granulomatous inflamma-
tory infiltration of the choroid and areas of necrosis under the
retinal pigment epithelium(3,26). Furthermore, the parasite’s
DNA can be identified in vitreous and humour samples using
PCR(21,28). Serum levels of chemokines (CXCL8) can also be used,
mainly during follow-up(29).
In our study, there were no differences between the cases
of ocular toxoplasmosis regarding the extension of retinal
necrosis, the number of T. gondii cysts, the granulomatous cho-
roiditis and the presence of T and B lymphocytes. However,
CD25 showed a differential expression, depending on IgM
status. All known cases of acquired toxoplamosis (IgM positive)
were positive, while IgM negative cases were mostly negative.
It has been previously reported that patients with a diag-
nosis of congenital ocular toxoplasmosis secrete significantly
less IL-2 in response to soluble toxoplasma tachyzoite antigen
(STAg) than do patients with a diagnosis of acquired toxoplas-
mosis(7). The detection of IL-2 in the serum has been used to
Table 1. Clinical data of the patients whose eye globes were
enucleated
Case Sex Age Laboratory Recurrence
1 M 37 IgM+ 3
2 F 61 IgM+ 4
3 F 58 IgM+ 3
4 M 63 IgM+ 2
5 M 72 IgM- 2
6 F 56 IgM- 4
7 F 43 IgM- 2
8 F 47 IgM- 3
9 M 56 IgM- 2
10 F 74 IgM- 2
Figure 1. Retinal necrosis containing viable and necrotic toxo cysts (between white
arrows). The asterisk shows the sub-RPE eosinophilic deposits corresponding to
areas of necrosis. The choroid is infiltrated with lymphocytes and macrophages
characterizing a chronic granulomatous inflammation (X 50 magnification).
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distinguish congenital from late acquired cases. Congenital
cases are consistently IL-2 negative while acquired toxoplas-
mosis are positive.
Our study is unique because we had enucleated eyes, so
we chose to study the expression of CD25, which is the trans-
membrane protein of the receptor of IL-2. As expected, all
confirmed acquired cases were positive for CD25. It is indeed
impossible to determine whether the cases of patients IgM
negative were congenital or late acquired ones. Interestingly,
we saw that four patients were negative, while two were posi-
tive. Considering the previous findings of Yamamoto et al.(7), it
is plausible that in this pilot study we were able to distinguish
acquired from congenital cases based on CD25 expression.
Consequently, further studies comparing confirmed cases of
congenital ocular toxoplasmosis to acquired ones are warran-
ted to substantiate our conclusions.
It has been suggested that the mechanisms involved in
the development of ocular lesions may be different in the two
forms of toxoplasmosis (congenital and acquired), despite the
similarity in the pathological characteristics(7). One hypothesis
proposes that patients with congenital disease could have
been T. gondii-specific T cells deleted or anergized through
exposure to toxoplasma antigens during the prenatal period,
which could explain the diminished response of T cells from
patients with congenital disease(7).
If the mechanisms of response to ocular toxoplasmosis
differs regarding it is congenital or acquired, it would be useful
to have specific treatments for each one, in order to obtain a
better outcome. Considering that ocular toxoplasmosis is a
recurrent disease, especially the congenital form(30), having a
method to distinguish both forms can be very useful, helping
in treatment and also in the management with different pro-
phylactic measures for recurrent lesions, for instance. Our fin-
dings suggest a possible laboratory tool to distinguish them.
 CONCLUSIONS
High expression of CD25 was found exclusively in acqui-
red cases of ocular toxoplasmosis.
To the best of our knowledge, this is the first report
showing that the use of CD25 as a marker for IL-2 is helpful to
differentiate acquired ocular toxoplasmosis. It further sup-
ports the theory that the IL-2 signalling axis may differ between
congenital and acquired cases of ocular toxoplasmosis.
Our findings are important because they provide a la-
boratory tool that could be used to differentiate between acqui-
red and congenital disease, and they may reinforce the hypo-
thesis that the mechanisms involved in the development of
ocular lesions may be different in the two forms of disease,
despite the similarity in the pathologic features.
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